CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Insmed Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Insmed Inc
700 Us Highway 202/206
Phone: (908) 977-9900p:908 977-9900 BRIDGEWATER, NJ  08807  United States Ticker: INSMINSM
Business Summary
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer William H.Lewis 55 1/1/2023 9/10/2012
Chief Financial Officer Sara M.Bonstein 43 1/31/2020 1/31/2020
Chief Operating Officer RogerAdsett 55 11/14/2019 9/27/2016
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
CELTRIX PHARMACEUTICALS INC 2033 GATEWAY PLACE SAN JOSE CA United States
Celtrix Pharmaceuticals 2033 Gateway Place, Suite 600 San Jose CA United States

Business Names
Business Name
Adrestia Therapeutics Inc.
Celtrix Pharmaceuticals, Inc.
INSM
14 additional Business Names available in full report.

General Information
Number of Employees: 912 (As of 12/31/2023)
Outstanding Shares: 178,902,721 (As of 10/25/2024)
Shareholders: 176
Stock Exchange: NASD
Federal Tax Id: 541972729
Email Address: investors@insmed.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024